Compare SFST & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SFST | TECX |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.0M | 549.5M |
| IPO Year | 2012 | N/A |
| Metric | SFST | TECX |
|---|---|---|
| Price | $58.03 | $30.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $64.00 | ★ $75.20 |
| AVG Volume (30 Days) | 113.7K | ★ 132.7K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $6,282,000.00 | N/A |
| Revenue This Year | $10.47 | N/A |
| Revenue Next Year | $12.19 | N/A |
| P/E Ratio | $49.14 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $35.36 | $14.39 |
| 52 Week High | $62.38 | $35.99 |
| Indicator | SFST | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 54.28 |
| Support Level | $53.96 | $27.31 |
| Resistance Level | $58.43 | $31.39 |
| Average True Range (ATR) | 1.91 | 1.89 |
| MACD | -0.16 | 0.12 |
| Stochastic Oscillator | 30.83 | 71.39 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.